News | February 13, 2026
Merck’s KEYTRUDA bags FDA nod for platinum-resistant ovarian cancer
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
Anand Chemiceutics serves over 1,500 laboratories, hospitals, and government institutions
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
Subscribe To Our Newsletter & Stay Updated
